Disclosed are bis(thio-hydrazide amide) disalts, which are represented by Structural Formula (I) €ƒ€ƒ€ƒ€ƒ€ƒ€ƒ€ƒ€ƒ 2 M + or M 2+ Y is a covalent bond or a substituted or unsubstituted straight chained hydrocarbyl group. R 1 -R 4 are independently -H, an aliphatic group, a substituted aliphatic group, an aryl group or a substituted aryl group, or R 1 and R 3 taken together with the carbon and nitrogen atoms to which they are bonded, and/or R 2 and R 4 taken together with the carbon and nitrogen atoms to which they are bonded, form a non-aromatic heterocyclic ring optionally fused to an aromatic ring. Z is -O or -S. M + is a pharmaceutically acceptable monovalent cation and M 2+ is a pharmaceutically acceptable divalent cation. Also disclosed are pharmaceutical compositions comprising a bis(thio-hydrazide amide) disalt described above. Further disclosed are methods of treating a subject with cancer. The methods comprise the step of administering an effective amount of a bis(thio-hydrazide amide) disalt.Jedinjenje formule (II):naznačeno time, što:R1 i R2 svaki nezavisno predstavlja supstituisanu ili nesupstituisanu fenil grupu, naznačenu time, što supstituente predstavljaju C1-C4 alkil, C1-C4 alkoksi, C1-C4 haloalkil, C1-C4 haloalkoksi, fenil, benzil, piridil, -OH, -NH2, -F, -Cl, -Br, -I, -NO2 ili -CN radikali；R3 i R4 svaki nezavisno predstavlja metil ili etil grupu；R5 predstavlja -H；R6 predstavlja -H ili metil grupu； iM+ predstavlja farmaceutski prihvatljiv monovalentni katjon, a M2+ predstavlja farmaceutski prihvatljiv dvovalentni katjon.Prijava sadrži još 46 patentnih zahteva.
